Comparison of Cryopreserved HepaRG Cells with Cryopreserved Human Hepatocytes for Prediction of Clearance for 26 Drugs

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Drug Metabolism And Disposition

• Publication date

  2012-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/dmd.111.042309PMID 21998403
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of intrinsic clearances in human liver microsomes and suspended hepatocytes from the same donor livers: clearance-dependent relationship and implications for prediction of in vivo clearance

  2011cited by this paper
• HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro.

  2011influential reference
• HepaRG cells: A human model to study mechanisms of acetaminophen hepatotoxicity

  2011influential reference
• Differential toxicity of heterocyclic aromatic amines and their mixture in metabolically competent HepaRG cells.

  2010influential reference
• Relationship between Passive Permeability, Efflux, and Predictability of Clearance from In Vitro Metabolic Intrinsic Clearance

  2010cited by this paper
• Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View

  2010cited by this paper
• Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems.

  2009cited by this paper
• Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells

  2009cited by this paper
• Functional expression, inhibition and induction of CYP enzymes in HepaRG cells.

  2009cited by this paper
• Running title page Running title : Functional stability of CYP P 450 enzymes in HepaRG cells

  2009influential reference
• Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance.

  2008cited by this paper
• Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies

  2008influential reference
• Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data

  2008cited by this paper
• Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance

  2007cited by this paper
• The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.

  2007cited by this paper
• Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

  2007cited by this paper
• EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS

  2006influential reference
• Comparison of the Use of Liver Models for Predicting Drug Clearance Using in Vitro Kinetic Data from Hepatic Microsomes and Isolated Hepatocytes

  2004cited by this paper
• Origin and characterization of a human bipotent liver progenitor cell line.

  2004cited by this paper
• Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.

  1997cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993influential reference
• Some suggestions for measuring predictive performance

  1981cited by this paper

• In vitro hepatic metabolism and associated binding of Enniatin B.

  2026cites this paper
• In vitro hepatic clearance of enniatin B1: interspecies and cell model comparison.

  2026cites this paper
• Mechanistic in vitro–in vivo extrapolation (IVIVE) approach using a biomimetic in vitro system for the prediction of hepatic clearance

  2025cites this paper
• In vitro to in vivo extrapolation from three-dimensional hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessment.

  2024cites this paper
• In Vitro Hepatic Metabolism Input Parameters Support Toxicokinetic Simulations for the Formation of Methoxy Propionic Acid From β‐Isomer Propylene Glycol Methyl Ether

  2024cites this paper
• In vitro-based prediction of human plasma concentrations of food-related compounds.

  2023cites this paper
• Metabolites in the regulatory risk assessment of pesticides in the EU

  2023cites this paper
• Analyzing the metabolic fate of oral administration drugs: A review and state-of-the-art roadmap

  2022cites this paper
• Candidate Proficiency Test Chemicals to Address Industrial Chemical Applicability Domains for in vitro Human Cytochrome P450 Enzyme Induction

  2022cites this paper
• Next Generation Risk Assessment of the Anti-Androgen Flutamide Including the Contribution of Its Active Metabolite Hydroxyflutamide

  2022cites this paper
• Exploration and application of a liver-on-a-chip device in combination with modelling and simulation for quantitative drug metabolism studies.

  2022cites this paper
• Variability in Human In Vitro Enzyme Kinetics.

  2021cites this paper
• Retinol from hepatic stellate cells via STRA6 induces lipogenesis on hepatocytes during fibrosis

  2021cites this paper
• P450s under Restriction (PURE) Screen Using HepaRG and Primary Human Hepatocytes for Discovery of Novel HBV Antivirals.

  2020cites this paper
• New approach methodologies (NAMs) for human-relevant biokinetics predictions: Meeting the paradigm shift in toxicology towards an animal-free chemical risk assessment.

  2020cites this paper
• Metabolic stability and its role in the discovery of new chemical entities

  2019cites this paper
• Quantitative in vitro-to-in vivo extrapolation (QIVIVE) of estrogenic and anti-androgenic potencies of BPA and BADGE analogues

  2019cites this paper
• Towards harmonization of test methods for in vitro hepatic clearance studies.

  2019cites this paper
• In vitro hepatotoxicity of Petasites hybridus extract (Ze 339) depends on the concentration, the cytochrome activity of the cell system, and the species used

  2019cites this paper
• Successful prediction of human pharmacokinetics after oral administration by optimized physiologically-based pharmacokinetics approach and permeation assay using human induced pluripotent stem cell-derived intestinal epithelial cells.

  2019cites this paper
• Prediction of Passive Membrane Permeability by Semi‐Empirical Method Considering Viscous and Inertial Resistances and Different Rates of Conformational Change and Diffusion

  2019cites this paper
• Establishing species-specific 3D liver microtissues for repeat dose toxicology and advancing in vitro to in vivo translation through computational modelling

  2018cites this paper
• HepaRG Cells as a Model for Hepatotoxicity Studies

  2018cites this paper
• Impact of cell types and culture methods on the functionality of in vitro liver systems - A review of cell systems for hepatotoxicity assessment.

  2018cites this paper
• Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures.

  2018cites this paper
• Evaluation of Generic Methods to Predict Human Pharmacokinetics Using Physiologically Based Pharmacokinetic Model for Early Drug Discovery of Tyrosine Kinase Inhibitors

  2018cites this paper
• Establishing a systematic framework to characterise in vitro methods for human hepatic metabolic clearance.

  2018cites this paper
• Evaluation of Drug Biliary Excretion Using Sandwich-Cultured Human Hepatocytes

  2018cites this paper
• Generation of Functional Hepatocytes from Human Adipose‐Derived MYC+ KLF4+ GMNN+ Stem Cells Analyzed by Single‐Cell RNA‐Seq Profiling

  2018cites this paper
• Advanced In Vitro HepaRG Culture Systems for Xenobiotic Metabolism and Toxicity Characterization

  2018cites this paper
• Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach

  2017cites this paper
• Stable Overexpression of the Constitutive Androstane Receptor Reduces the Requirement for Culture with Dimethyl Sulfoxide for High Drug Metabolism in HepaRG Cells

  2017cites this paper
• Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling

  2017cites this paper
• From in vitro to in vivo: Integration of the virtual cell based assay with physiologically based kinetic modelling

  2017cites this paper
• Fluorometric evaluation of CYP3A4 expression using improved transgenic HepaRG cells carrying a dual-colour reporter for CYP3A4 and CYP3A7

  2017cites this paper
• Non-animal approaches for toxicokinetics in risk evaluations of food chemicals.

  2017cites this paper
• Online monitoring of hepatic rat metabolism by coupling a liver biochip and a mass spectrometer.

  2017cites this paper
• Evaluation of a novel PXR‐knockout in HepaRG™ cells

  2016influential citation
• Prediction of Metabolic Clearance for Low-Turnover Compounds Using Plated Hepatocytes with Enzyme Activity Correction

  2016cites this paper
• Prediction of inter-individual variability on the pharmacokinetics of CYP1A2 substrates in non-smoking healthy volunteers.

  2016cites this paper
• Optimisation of in vitro methodology for drug metabolism studies to improve prediction of hepatic drug clearance

  2016cites this paper
• The role of drug metabolism in drug discovery and development : case ospemifene

  2015cites this paper
• HUMAN IN VITRO LIVER CELL SYSTEMS

  2015cites this paper
• Understanding the biokinetics of ibuprofen after single and repeated treatments in rat and human in vitro liver cell systems.

  2015cites this paper
• How to Choose In Vitro Systems to Predict In Vivo Drug Clearance: A System Pharmacology Perspective

  2015cites this paper
• Kinetics and dynamics of cyclosporine A in three hepatic cell culture systems.

  2015cites this paper
• Biotransformation in vitro: An essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data.

  2015cites this paper
• Development of 3D Dynamic Flow Model of Human Liver and Its Application to Prediction of Metabolic Clearance of 7-Ethoxycoumarin

  2014cites this paper
• Consideration of Metabolism in In Vitro Cellular Systems

  2014cites this paper
• Considerations in the development of in vitro toxicity testing methods intended for regulatory use

  2014cites this paper
• PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop.

  2014cites this paper
• Evaluation of a liver microfluidic biochip to predict in vivo clearances of seven drugs in rats.

  2014cites this paper
• A Useful Model Capable of Predicting the Clearance of Cytochrome P450 3A4 (CYP3A4) Substrates in Humans: Validity of CYP3A4 Transgenic Mice Lacking Their Own Cyp3a Enzymes

  2014cites this paper
• Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors

  2014influential citation
• Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling.

  2014cites this paper
• High Content Imaging and Analysis Enable Quantitative In Situ Assessment of CYP3A4 Using Cryopreserved Differentiated HepaRG Cells

  2014cites this paper
• Transcriptional regulation of human UDP-glucuronosyltransferase genes

  2014cites this paper
• CYP3A4 activity reduces the cytotoxic effects of okadaic acid in HepaRG cells

  2014cites this paper
• Defining the Relationship between the Bioactivation of Lapatinib by CYP3A and Lapatinib-Induced Hepatotoxicity

  2014cites this paper
• Absorption of TAK-491, a new angiotensin II receptor antagonist, in animals

  2013cites this paper
• Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME

  2013cites this paper
• Differential regulation of drug transporter expression by all-trans retinoic acid in hepatoma HepaRG cells and human hepatocytes.

  2013cites this paper
• In Vitro Evaluation of Major In Vivo Drug Metabolic Pathways Using Primary Human Hepatocytes and HepaRG Cells in Suspension and a Dynamic Three-Dimensional Bioreactor System

  2012cites this paper
• Quantification of cytochromes P450, ABC transporters and their main transcription factors in the brains of alcoholics, smokers and drug-free controls by QRT-PCR

  2012cites this paper
• The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human

  2012cites this paper
• Evaluation of the novel in vitro systems for hepatic drug clearance and assessment of their predictive utility.

  2012cites this paper
• Human liver in vitro models for evaluation of drug metabolism and disposition

  2012cites this paper
• Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs.

  2012cites this paper
• Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results

  2012cites this paper
• Optimization of the HepaRG cell model for drug metabolism and toxicity studies.

  2012cites this paper
• Stem Cell-Based Toxicity Screening: Recent Advances in Hepatocyte Generation

  2012cites this paper
• Stem Cell-Based Toxicity Screening

  2012cites this paper